Insulin-Mediated Diseases: Adrenal Mass and Polycystic Ovary Syndrome

Trends in Endocrinology and Metabolism

Volumn 26, Issue 10, 2015, Pages 512-514

  Muscogiuri, Giovanna ^a   Colao, Annamaria ^a   Orio, Francesco ^b,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^c S Giovanni di Dio e Ruggi d'Aragona Hospital   (Italy)

Author keywords

Adrenal incidentaloma; Insulin resistance; PCOS; Type 2 diabetes

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; INSULIN; INSULIN RECEPTOR;

ADRENAL GLAND; ADRENAL INCIDENTALOMA; CANCER INCIDENCE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE ASSOCIATION; HORMONE RELEASE; HUMAN; HYDROCORTISONE RELEASE; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MANAGED CARE; OVARY CYST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SHORT SURVEY; ADRENAL GLAND NEOPLASMS; COMPLICATION; FEMALE; HYPERINSULINISM; METABOLISM; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME;

ADRENAL GLAND NEOPLASMS; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

EID: 84942089807     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.07.010     Document Type: Short Survey

References (13)

1. Chidiac R.M., Aron D.C. Incidentalomas. A disease of modern technology. Endocrinol. Metab. Clin. North Am. 1997, 26:233-253.
2. Terzolo M., et al. Adrenal incidentaloma: a new cause of the metabolic syndrome?. J. Clin. Endocrinol. Metab. 2002, 87:998-1003.
3. Anderwald C., et al. The Clamp-Like Index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. Diabetes Care 2007, 30:2374-2380.
4. Anderwald C.H., et al. Adequately adapted insulin secretion and decreased hepatic insulin extraction cause elevated insulin concentrations in insulin resistant non-diabetic adrenal incidentaloma patients. PLoS ONE 2013, 8:e77326.
5. Muscogiuri G., et al. The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship?. Clin. Endocrinol. 2011, 74:300-305.
6. Androulakis I.I., et al. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J. Clin. Endocrinol. Metab. 2014, 99:2754-2762.
7. Ceccato F., et al. Performance of salivary cortisol in the diagnosis of Cushing's syndrome, adrenal incidentaloma, and adrenal insufficiency. Eur. J. Endocrinol. 2013, 169:31-36.
8. Garrapa G.G., et al. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. J. Clin. Endocrinol. Metab. 2001, 86:5301-5306.
9. Carmina E., et al. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. Fertil. Steril. 2005, 84:413-419.
10. Münzker J., et al. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2015, 100:653-660.
11. Puurunen J., et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J. Clin. Endocrinol. Metab. 2011, 96:1827-1834.
12. Jones H., et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J. Clin. Endocrinol. Metab. 2012, 97:3709-3716.
13. Moghetti P., et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J. Clin. Endocrinol. Metab. 1996, 81:952-960.